Insigneo Advisory Services LLC Sells 2,673 Shares of Johnson & Johnson (NYSE:JNJ)

Insigneo Advisory Services LLC decreased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 11.6% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,417 shares of the company's stock after selling 2,673 shares during the quarter. Insigneo Advisory Services LLC's holdings in Johnson & Johnson were worth $2,953,000 at the end of the most recent quarter.

Other large investors also recently made changes to their positions in the company. Stenger Family Office LLC bought a new position in Johnson & Johnson during the fourth quarter worth about $2,158,000. NFJ Investment Group LLC acquired a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $10,774,000. Finward Bancorp bought a new position in Johnson & Johnson during the fourth quarter worth $1,554,000. United Capital Financial Advisors LLC raised its position in shares of Johnson & Johnson by 10.1% in the fourth quarter. United Capital Financial Advisors LLC now owns 291,841 shares of the company's stock valued at $42,206,000 after purchasing an additional 26,674 shares during the period. Finally, Delaney Dennis R grew its stake in Johnson & Johnson by 1.9% in the 4th quarter. Delaney Dennis R now owns 40,032 shares of the company's stock valued at $5,789,000 after buying an additional 730 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Insider Activity at Johnson & Johnson

In related news, EVP Timothy Schmid sold 403 shares of Johnson & Johnson stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now owns 15,098 shares of the company's stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company's stock, valued at approximately $3,483,645.88. This trade represents a 25.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the company. Stifel Nicolaus decreased their target price on Johnson & Johnson from $170.00 to $155.00 and set a "hold" rating on the stock in a research report on Thursday, January 23rd. Bank of America lowered their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating on the stock in a research report on Thursday, April 10th. Wells Fargo & Company decreased their price target on shares of Johnson & Johnson from $166.00 to $152.00 and set an "equal weight" rating on the stock in a research note on Thursday, January 23rd. Sanford C. Bernstein reiterated a "market perform" rating on shares of Johnson & Johnson in a research note on Wednesday. Finally, Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an "outperform" rating on the stock in a research report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, nine have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has an average rating of "Moderate Buy" and an average target price of $171.72.

Johnson & Johnson Price Performance

Shares of JNJ traded up $3.51 during trading hours on Friday, reaching $157.42. The stock had a trading volume of 10,972,370 shares, compared to its average volume of 7,960,814. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $169.99. The company's 50-day moving average is $159.47 and its two-hundred day moving average is $155.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The stock has a market capitalization of $379.37 billion, a PE ratio of 23.67, a PEG ratio of 2.56 and a beta of 0.49.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business had revenue of $21.89 billion during the quarter, compared to analyst estimates of $21.65 billion. Research analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th will be paid a $1.30 dividend. This is a boost from Johnson & Johnson's previous quarterly dividend of $1.24. The ex-dividend date of this dividend is Tuesday, May 27th. This represents a $5.20 annualized dividend and a dividend yield of 3.30%. Johnson & Johnson's dividend payout ratio is presently 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.